$0.53
4.95%
Nasdaq, Fri, Dec 27 2024
ISIN
US00444T1007
Symbol
ACRX
Sector
Industry

AcelRx Pharmaceuticals, Inc. Stock price

$0.53
-0.19 26.64% 1M
-0.38 41.76% 6M
-0.21 27.89% YTD
-0.24 31.17% 1Y
-9.91 94.93% 3Y
-44.27 98.82% 5Y
-138.87 99.62% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.03 4.95%
ISIN
US00444T1007
Symbol
ACRX
Sector
Industry

Key metrics

Market capitalization $9.03m
Enterprise Value $4.44m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 15.86
P/S ratio (TTM) P/S ratio 32.25
P/B ratio (TTM) P/B ratio 0.94
Revenue growth (TTM) Revenue growth -54.82%
Revenue (TTM) Revenue $280.00k
EBIT (operating result TTM) EBIT $-16.54m
Free Cash Flow (TTM) Free Cash Flow $-14.38m
Cash position $11.12m
EPS (TTM) EPS $-0.68
P/E forward negative
Short interest 3.75%
Show more

Is AcelRx Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

AcelRx Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:

Buy
100%

Financial data from AcelRx Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.28 0.28
55% 55%
100%
- Direct Costs 0.10 0.10
-
36%
0.19 0.19
-
68%
- Selling and Administrative Expenses 9.56 9.56
35% 35%
3,414%
- Research and Development Expense 7.07 7.07
57% 57%
2,525%
-16 -16
15% 15%
-5,871%
- Depreciation and Amortization 0.10 0.10
85% 85%
36%
EBIT (Operating Income) EBIT -17 -17
17% 17%
-5,907%
Net Profit -16 -16
27% 27%
-5,589%

In millions USD.

Don't miss a Thing! We will send you all news about AcelRx Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.

Head office United States
CEO Vincent Angotti
Employees 15
Founded 2005
Website talphera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today